TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating

TD Cowen维持Sangamo Therapeutics(SGMO.US)买入评级

moomoo资讯 · 11/14 08:31 · 评级/大行评级

TD Cowen analyst Ritu Baral maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating.

According to TipRanks data, the analyst has a success rate of 51.0% and a total average return of 15.6% over the past year.

AnalystRecentRatingAutoNews_206543_20241114_ab79124d2184ca3e6ee89b1e8672deb60a22bb9a_1731591005413649_mm_en

Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:

Subsequent to the Q3 report, there is an alignment with the FDA on an accelerated approval pathway. The discussion during the Q3 call was centered on the advancement of the Fabry program, with partnership negotiations reportedly in the advanced stages. There is an anticipation of favorable data by Q3 of 2025, followed by potential FDA approval in 2026, and a deal announcement is expected in the near future.
The firm perceives the establishment of partnerships on the Fabry program and the comprehensive results from the pivotal study as pivotal catalysts. It is believed that the stock's upside will be propelled by proof of concept of the company's wholly owned ZFP transcription factor neurology programs.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

TD Cowen分析师Ritu Baral维持$Sangamo Therapeutics (SGMO.US)$买入评级。

根据TipRanks数据显示，该分析师近一年总胜率为51.0%，总平均回报率为15.6%。

AnalystRecentRatingAutoNews_206543_20241114_ab79124d2184ca3e6ee89b1e8672deb60a22bb9a_1731591005413649_mm_sc

此外，综合报道，$Sangamo Therapeutics (SGMO.US)$近期主要分析师观点如下：

在Q3报告之后，与FDA达成了加速批准途径的一致意见。Q3电话会议期间的讨论主要集中在爱文思控股Fabry项目的推进上，据称合作谈判已经进入了高级阶段。预计到2025年Q3会有有利数据出现，随后可能在2026年获得FDA批准，预计近期将宣布交易。
公司认为在Fabry项目上建立合作伙伴关系以及关键研究的全面结果是关键推动因素。预计公司自有的ZFP转录因子神经学项目的概念验证将推动股价上涨。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating

TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating

风险及免责提示

声明